Company Profile
CircuLite® is developing disruptive solutions to improve the treatment of chronic heart failure. The Company's minimally-invasive circulatory support systems are intended to work in conjunction with the heart to enhance clinical outcomes and improve quality of life for patients and their families. Synergy®, currently in a CE Mark clinical trial, features the world's smallest surgically implanted blood pump designed for long-term use in patients diagnosed with chronic heart failure. Next-generation circulatory support systems in development that incorporate CircuLite's micro-pump technology include an endovascular system, a right-heart system, a pediatric system, and an all-support system.
CircuLite's devices are being developed for patients with chronic heart failure who are not responding to standard medical care, but are not candidates or eligible for heart transplantation. The majority of these patients will have been diagnosed with NYHA Class IIIb/early Class IV (INTERMACS 4-6) heart failure. Synergy is a miniature ventricular support system that is intended to offer patients clinical benefits over standard medical therapies, including reduced symptoms of heart failure and associated re-hospitalizations, as well as to improve exercise tolerance and quality of life.
Synergy's Micro-pump is the size of a AA battery, provides up to 4.25 liters of blood flow per minute, and is designed to reduce the heart's workload while improving blood flow to vital organs. Synergy supplements the heart's native pumping capacity and preserves its ability to respond to the patient's cardiac output demands. The system is surgically implanted using a mini-thoracotomy and the Micro-pump is placed in a pacemaker-like pocket.
CircuLite, a private, venture-backed international company, was founded 2004. CircuLite, Inc. Is headquartered in Saddle Brook, New Jersey. CircuLite GmbH, the exclusive licensee to manufacture and distribute CircuLite product for the European Union and Switzerland, is located in Aachen, Germany.